Estimated reading time: 1 minutes
FDA approved Bkemv as the first interchangeable biosimilar to Soliris (eculizumab) to treat certain rare diseases. Bkemv is approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH); and atypical hemolytic uremic syndrome (aHUS).
About The Author
Discover more from Life is Pro-Mazing!
Subscribe to get the latest posts sent to your email.